Abstract
Recent findings have thrust poly(ADP-ribose) polymerases (PARPs) into the limelight as potential chemotherapeutic targets. To provide a framework for understanding these recent observations, we review what is known about the structures and functions of the family of PARP enzymes, and then outline a series of questions that should be addressed to guide the rational development of PARP inhibitors as anticancer agents.
Original language | English (US) |
---|---|
Pages (from-to) | 293-301 |
Number of pages | 9 |
Journal | Nature Reviews Cancer |
Volume | 10 |
Issue number | 4 |
DOIs |
|
State | Published - Apr 2010 |
ASJC Scopus subject areas
- Oncology
- Cancer Research